Sanofi has won FDA approval for its sutimlimab ... The complement C1s-targeting antibody – given the brand name Enjaymo – has been cleared decrease the need for blood transfusions in patients ...
In sustained rare disease push, Recordati lays out $825M upfront to acquire Sanofi's CAD drug Enjaymo Meanwhile, Sanofi saw revenues for its consumer health arm, Opella, grow 7.9%. Earlier this ...
New drug Enjaymo recorded sales of €28 million in the quarter compared with €26 million in the previous quarter. Sanofi has sold global rights to Enjaymo to Recordati. The transaction is ...
Recordati Industria Chimica e Farmaceutica SPA (IT:REC) has released an update. Recordati Industria Chimica e Farmaceutica SPA reported strong ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback